All In Biotech

Drug Trial Radar · NCT07489573

Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa

An Open-label, Multicenter Study Assessing Efficacy and Safety of Secukinumab up to One Year in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Sep 25, 2029

Study completion Nov 5, 2029

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe hidradenitis suppurativa (HS).

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

  • SecukinumabDrug

    secukinumab 300 mg s.c. administered Q2W or Q4W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants achieving HiSCR50 at Week 16Time frame: Week 16

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Shanghai, China · Recruiting

  • Novartis Investigative Site

    Tianjin, China · Recruiting

  • Novartis Investigative Site

    Guangzhou, Guangdong, China · Recruiting

  • Novartis Investigative Site

    Shijiazhuang, Hebei, China · Recruiting

  • Novartis Investigative Site

    Chengdu, Sichuan, China · Recruiting

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China · Recruiting

  • Novartis Investigative Site

    Ningbo, Zhejiang, China · Recruiting

  • Novartis Investigative Site

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.